Management of Muscle Invasive Bladder Cancer

1. Introduction to muscle invasive bladder cancer.- 2. Epidemiology and risk factors in muscle invasive bladder cancer.- 3. The molecular basis of muscle invasive bladder cancer.- 4. Histological variants in MIBC - squamous cell and squamous differentiation.- 5. Histological variants in muscle invasive bladder cancer - adenocarcinoma.- 6. Histological variants in muscle invasive bladder Cancer - sarcomatoid cancer.- 7. MIBC Carcinosarcoma.- 8. Muscle invasive bladder cancer- small cell.- 9. MIBC plasmacytoid.- 10. MIBC  and micropapillary bladder cancer.- 11. MIBC bladder cancer assessment and diagnosis.- 12. A systematic review on blue light cystoscopy in bladder cancer diagnostics.- 13. A systematic review on the staging conundrum in bladder cancer.- 14. Current state of investigations and limitations in muscle invasive bladder cancer.- 15. Risk stratification in bladder cancer.- 16. Preventative measures for those with high risk MIBC.- 17. Bladder cancer risk post pelvic irradiation.- 18. A systematic review on bladder preservation strategies and MIBC.- 19. Partial cystectomy.- 20. Muscle invasive bladder cancer and neoadjuvant chemotherapy.- 21. Controversies in clinical effectiveness of neoadjuvant chemotherapy.- 22. Trimodal therapy in bladder cancer.- 23. Systematic review on trimodal therapy in bladder cancer.- 24. Trimodal therapy - a systematic review.- 25. Reviews related to trimodal therapy for MIBC.- 26. Radical cystectomy lap open robotic.- 27. Prostate sparing cystectomy - a systematic review.- 28. A systematic review on nerve sparing cystoprostatectomy.- 29. MIBC - orthotopic vs ileal conduit.- 30. MIBC - a systematic review on orthotopic neobladder vs. ileal conduit.- 31. MIBC and radical cystectomy in the elderly.- 32. MIBC radical radiotherapy.- 33. MIBC - quality of life with urinary diversion.- 34. Neoadjuvant chemotherapy for muscle invasive bladder cancer.- 35. Muscle invasive bladder cancer and the staging conundrum.- 36. Radical

Miss Sanchia S. Goonewardene, MBChB (Hons.Clin.Sc), BMedSc(Hons), PGCGC, Dip.SSc, MRCS (Ed and Eng) MPhil. Sanchia Goonewardene qualified from Birmingham Medical School with Honours in Clinical Science and a BMedSc Degree in Medical Genetics and Molecular Medicine. She has a specific interest in academia during her spare time, with over 627 publications to her name with 2 papers as a number 1 most cited in fields (Biomedical Library), and has significantly contributed to the Urological Academic World- she has since added a section to the European Association of Urology Congress on Prostate Cancer Survivorship and Supportive Care and is an associate member of an EAU guidelines panel on Chronic Pelvic Pain. She has been the UK lead in an EAU led study on Salvage Prostatectomy. She has also contributed to the BURST IDENTIFY study as a collaborator. Her background with research entails an MPhil, the work from which went on to be drawn up as a document for PCUK then, NICE endorsed. She gained funding from the Wellcome Trust for her Research Elective. She is also an Alumni of the Urology Foundation. She is an Editorial board member of the World Journal of Urology and was invited to be Guest Editor for a Special Issue on Salvage Therapy in Prostate Cancer. She is also a review board member for BMJ case reports. Most recently she has been a  ICS Ambassador, ICS Mentor, ICS abstract reviewer and has been a Session Chair at YAU-ERUS, where she has presented her work. 

Mr Hanif Motiwala, MB, BS, MS, FRCS (Edin)), FRCS (Urol),. Mr  Hanif Motiwala is a Senior Pelvic and Reconstructive Urologist working at Southend University Hospital and Essex Cancer Centre. He has spent over 25 years in Pelvic surgery with 1000+ pelvic operations comprising both radical and salvage surgeries.  He is  well known to the urology community worldwide. He was Professor of Urology in India and has also served as an FRCS Urol